A retrospective study on bone metastasis in dogs with advanced-stage solid cancer.
Journal
The Journal of small animal practice
ISSN: 1748-5827
Titre abrégé: J Small Anim Pract
Pays: England
ID NLM: 0165053
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
23
03
2023
received:
01
08
2022
accepted:
09
04
2023
medline:
12
9
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
To review clinical characteristics, treatment, outcome and prognostic factors in dogs with solid cancer-bearing bone metastases. Records were reviewed from dogs with histologically-proven solid cancer and bone metastases. Clinicopathologic variables, bone metastases characteristics and skeletal-related events were recorded. Endpoints were time to bone metastases and survival. Fifty dogs were included, 20 of them with synchronous and 30 of them with metachronous bone metastases. In the latter group, median time to diagnosis of bone metastases was 210 days (range, 30 to 1835). Most common primary cancer locations included mammary gland (n=6), spleen (n=5) and tonsil (n=5). Most common histotypes were carcinoma (n=32) and hemangiosarcoma (n=10). Nineteen dogs had multiple bones involvement, with humeri and vertebrae more commonly affected. Twenty-four dogs received antitumoural therapy, five symptomatic treatment and 21 were not treated. Overall median survival after bone metastases diagnosis was 30 days (range, 11 to 49); 83% of dogs died because of skeletal-related events. Lack of antitumoural therapy was significantly associated with shorter survival (hazard ratio: 2.7; 95% confidence interval: 1.3 to 5.6) and with increased risk of skeletal-related death (hazard ratio: 3.3; 95% confidence interval: 1.4 to 7.4). Dogs with endocrine/neuroendocrine tumours (odds ratio: 8.8; 95% confidence interval: 1.2 to 63.9), without appendicular metastases (odds ratio: 5.1; 95% confidence interval: 1.0 to 25.8), without extra-skeletal metastases (odds ratio: 5.2; 95% confidence interval: 1.1 to 24.5) and receiving antitumoural therapy (odds ratio: 14.8; 95% confidence interval: 1.7 to 131.4) had an increased chance of surviving more than 100 days. Bone metastases in dogs with solid cancers are associated with poor prognosis and a high risk of skeletal-related events. Treatment appears to have an impact on survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
561-567Informations de copyright
© 2023 British Small Animal Veterinary Association.
Références
Charney, V. A., Miller, M. A., Heng, H. G., et al. (2016) Skeletal metastasis of canine urothelial carcinoma: pathologic and computed tomographic features. Veterinary Pathology 54, 380-386
Coleman, R. E. (1997) Skeletal complications of malignancy. Cancer 80, 1588-1594
Cooley, D. M. & Waters, D. J. (1998) Skeletal metastasis as the initial clinical manifestation of metastatic carcinoma in 19 dogs. Journal of Veterinary Internal Medicine 12, 288-293
Ehrhart, N. P., Christensen, N. I. & Fan, T. M. (2020) Tumors of the skeletal system. In: Withrow & MacEwen's Small Animal Clinical Oncology. 6th edn. Eds D. M. Vail, D. H. Thamm and J. M. Liptak. Elsevier, St. Louis, MO, USA. pp 524-564
Fan, T. M., de Lorimier, L. P., Charney, S. C., et al. (2005) Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. Journal of Veterinary Internal Medicine 19, 74-80
Frank, S., Carton, M., Dubot, C., et al. (2020) Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. Breast 52, 50-57
Glinsky, V. V. (2006) Intravascular cell-to-cell adhesive interactions and bone metastasis. Cancer and Metastasis Reviews 25, 531-540
Hage, W. D., Aboulafia, A. J., Aboulafia, D. M., et al. (2000) Incidence, location, and diagnostic evaluation of metastatic bone disease. The Orthopedic Clinics of North America 31, 515-528
Hammer, A., Weeren, F., Weisbrode, S., et al. (1995) Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. Journal of the American Animal Hospital Association 31, 321-326
Holbrook, N. J. & Ikeyama, S. (2002) Age-related decline in cellular response to oxidative stress: links to growth factor signaling pathways with common defects. Biochemical Pharmacology 64, 999-1005
Jiang, W., Rixiati, Y., Zhao, B., et al. (2020) Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. Journal of Orthopaedic Surgery 28, 2
Li, S., Peng, Y., Weinhandl, E. D., et al. (2012) Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clinical Epidemiology 4, 87-93
Lipton, A. & Balakumaran, A. (2012) Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Review of Clinical Pharmacology 5, 359-371
Lipton, A., Theriault, R. L., Hortobagyi, G. N., et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88, 1082-1090
Makielski, K. M., Mills, L. J., Sarver, A. L., et al. (2019) Risk factors for development of canine and human osteosarcoma: a comparative review. Veterinary Sciences 6, 48-67
Melilli, A. (2020) Uncommon skeletal metastasis secondary to transitional cell carcinoma. Open Veterinary Journal 9, 313-316
Michalak, S. R., Woerde, D. J., Wilson, S. S., et al. (2021) Mandibular metastasis of a prostatic carcinoma in a dog. Veterinary Medicine and Science 7, 1488-1492
Nakamoto, Y., Osman, M. & Wahl, R. L. (2003) Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clinical Nuclear Medicine 28, 302-307
Nguyen, D. X., Bos, P. D. & Massagué, J. (2009) Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer 9, 274-284
Norgaard, M., Jensen, A. O., Jacobsen, J. B., et al. (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). Journal of Urology 184, 162-167
Pagani, F., Francucci, C. M. & Moro, L. (2005) Markers of bone turnover: biochemical and clinical perspectives. Journal of Endocrinological Investigation 28, 8-13
Paget, S. (1889) The distribution of secondary growths in cancer of the breast. The Lancet 133, 571-573
Phadke, P. A., Mercer, R. R., Harms, J. F., et al. (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clinical Cancer Research 12, 1431-1440
Purushotham, A., Shamil, E., Cariati, M., et al. (2014) Age at diagnosis and distant metastasis in breast cancer - a surprising inverse relationship. European Journal of Cancer 50, 1697-1705
Reed, M. J., Karres, N., Eyman, D., et al. (2007) The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. International Journal of Cancer 120, 753-760
Riihimäki, M., Hemminki, A., Fallah, M., et al. (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86, 78-84
Roodman, G. D. (2004) Mechanisms of bone metastasis. New England Journal of Medicine 350, 1655-1664
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors. Cancer 100, 2613-2621
Rove, K. O. & Crawford, E. D. (2009) Metastatic cancer in solid tumors and clinical outcome: skeletal-related events. Oncology 23, 21-27
Ru, G., Terracini, B. & Glickman, L. T. (1998) Host related risk factors for canine osteosarcoma. The Veterinary Journal 156, 31-39
Sathiakumar, N., Delzell, E., Morrisey, M. A., et al. (2011) Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer and Prostatic Diseases 14, 177-183
Sathiakumar, N., Delzell, E., Morrisey, M. A., et al. (2012) Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Research and Treatment 131, 231-238
Sathiakumar, N., Delzell, E., Morrisey, M., et al. (2013) Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Lung India 30, 20-26
Schultz, R. M., Puchalski, S. M., Kent, M., et al. (2007) Skeletal lesions of histiocytic sarcoma in nineteen dogs. Veterinary Radiology & Ultrasound 48, 539-543
Shupp, A. B., Kolb, A. D., Mukhopadhyay, D., et al. (2018) Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers 10, 182-219
Spugnini, E. P., Vincenzi, B., Caruso, Q., et al. (2009) Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. Journal of Small Animal Practice 50, 44-46
Suva, L. J., Cooper, A., Watts, A. E., et al. (2021) Bisphosphonates in veterinary medicine: the new horizon for use. Bone 142, 115711
Trost, M. E., Inkelmann, M. A., Galiza, G. J. N., et al. (2014) Occurrence of tumours metastatic to bones and multicentric tumours with skeletal involvement in dogs. Journal of Comparative Pathology 150, 8-17
Welch, D. R., Harms, J. F., Mastro, A. M., et al. (2003) Breast cancer metastasis to bone: evolving models and research challenges. Journal of Musculoskeletal & Neuronal Interactions 3, 30-38
Yong, M., Jensen, A. Ø., Jacobsen, J. B., et al. (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Research and Treatment 129, 495-503